Special

Translational Cancer Research

Translational cancer research is forging ahead at an increasing pace. As the molecular pathways that are disturbed in cancer are being unravelled, new therapeutic targets are being identified and novel drugs are being developed. These advances are being translated into clinical trials with a view to providing personalized cancer care, in which the genetic makeup of an individual tumour and other biomarkers can predict the combination of treatments that it will best respond to.

Credit: Grant McArthur, Jason Callahan and Rod Hicks, Peter MacCallum Cancer Centre, Australia

News and Comment
Current Research
Archive
Links
Sponsor

News and Comment

EDITORIAL: Hope in translation

Nature 467 , 499 ( 30 September 2010 )
Rare victory in fight against melanoma

Heidi Ledford

Nature 467 , 140–141 ( 7 September 2010 )
Bone-disease drug could treat breast cancer

Ewen Callaway

Nature doi:10.1038/news.2010.504 ( 29 September 2010 )

Current Research

Translating cancer research into targeted therapeutics

J. S. de Bono & Alan Ashworth

Nature 467 , 543-549 ( 30 September 2010 )
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag et al.

Nature 467 , 596-599 ( 30 September 2010 )
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

Eva Gonzalez-Suarez et al.

Nature doi:10.1038/nature09495 ( 29 September 2010 )
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer

Daniel Schramek et al.

Nature doi:10.1038/nature09387 ( 29 September 2010 )
Selective inhibition of BET bromodomains

Panagis Filippakopoulos et al.

Nature doi:10.1038/nature09504 ( 24 September 2010 )
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Mark E. Davis et al.

Nature 464 , 1067–1070 ( 15 April 2010 )
Therapeutic antibody targeting of individual Notch receptors

Yan Wu et al.

Nature 464 , 1052–1057 ( 15 April 2010 )
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Georgia Hatzivassiliou et al.

Nature 464 , 431–435 ( 18 March 2010 )
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikos I. Poulikakos, Chao Zhang, Gideon Bollag, Kevan M. Shokat & Neal Rosen

Nature 464 , 427–430 ( 18 March 2010 )
Drug discovery: Inhibitors that activate

Karen Cichowski & Pasi A. Jänne

Nature 464 , 358–359 ( 18 March 2010 )
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Jianming Zhang et al.

Nature 463 , 501–506 ( 28 January 2010 )

Translational Cancer Research

News and Comment

Current Research

Archive

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hannah Farmer et al. Nature 434 , 917–921 ( 14 April 2005 )

Links

Sponsor:

Science jobs

NatureJobs.com

Science events

NatureEvents Directory

Most read

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer et al.

Nature 434 , 917–921 ( 14 April 2005 )